---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-331207"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2026-08-04T01:54:29+00:00"
generated_at: "2026-08-04T10:05:33.931432+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics completes merger with Obsidian; becomes subsidiary of Obsidian Therapeutics

## Summary
- Galera shareholders receive 0.7019 shares of Parent common stock per share; Legacy Obsidian shareholders receive 0.1383 shares per share.
- Post-merger ownership: Legacy Obsidian ~51.6%, PIPE investors ~47.2%, Galera ~1.2% on fully diluted basis.
- Galera shareholders receive CVRs: 80% of net proceeds from Legacy Product (tilarganine) over 5 years, 95% from Supportive-Care divestiture over 10 years.
- Galera common stock to be delisted from OTCQB; company to file Form 15 to terminate SEC registration.
- All prior directors resigned; new officers appointed (Madan Jagasia, Julie Feder, Parameswaran Hari, Dana Alexander).

## SEC filing metadata
- accession: 0001193125-26-331207
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2026-08-04T01:54:29+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312526331207/0001193125-26-331207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312526331207/d170816d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-331207
- JSON: https://secwatch.observer/filing/0001193125-26-331207.json
- Plain text: https://secwatch.observer/filing/0001193125-26-331207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.